Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study reported that dupilumab successfully induced remission of chronic, disseminated eczema herpeticum in a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, achieving complete resolution of herpetic lesions and significant skin, hair, and nail improvement within three months.

This study reports that among patients treated with dupilumab, a minority developed new-onset alopecia areata, but the majority experienced hair regrowth despite continuing the treatment.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This case report documented a 74-year-old female with alopecic patches and other skin issues during talquetamab therapy for multiple myeloma, suggesting that the drug may cause skin-related adverse effects due to reactivity to GPRC5D-expressing structures.

In this case report, a 2-year-old girl with severe alopecia areata experienced significant hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but the combination of treatments and possible spontaneous recovery mean the improvement cannot be solely credited to dupilumab.

This study found that psoriasis patients on biologic therapy had significantly lower anti-COVID19 IgG antibody levels after vaccination compared to healthy individuals not on biologic treatment.

This study found that combining hair transplantation with platelet-rich plasma treatment significantly improved hair regeneration, reduced hair loss, and minimized skin lesion areas in patients with androgenic alopecia compared to hair transplantation alone, suggesting enhanced treatment efficacy.

In this case report, a woman developed severe alopecia areata approximately one year after starting belimumab for systemic lupus erythematosus, with hair loss improving upon discontinuation of the drug, suggesting a possible connection between belimumab and immune-mediated hair loss.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This article discusses the withdrawal of bamlanivimab monotherapy's emergency use authorization in the U.S. due to evolving COVID-19 variants and offers no new clinical data.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This case report describes a 56-year-old woman with rheumatoid arthritis who developed alopecia universalis during treatment with the TNF inhibitor adalimumab, with no hair regrowth after stopping the medication.

This case report highlights a woman who developed new-onset alopecia areata after starting adalimumab for psoriatic arthritis, challenging the assumed role of TNF-alpha in the condition's pathogenesis.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study observed that some patients experienced alopecia areata during dupilumab treatment for atopic dermatitis, but many regrew hair while continuing therapy.

This study identified both known and additional potential adverse reactions to tralokinumab in real-world use for atopic dermatitis, highlighting the importance of monitoring adverse events, especially in the first month of treatment.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This paper argues that for lupus management, selective immunotherapies like anifrolumab and belimumab, which specifically target parts of the immune system, offer more effective treatment options compared to older, broad immunosuppressive strategies.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

This study reports that a 9-week-old infant with Netherton syndrome showed rapid and sustained symptom improvement, including skin microbiome normalization and developmental progress, after off-label dupilumab treatment, without adverse reactions.

In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.